Objective: Patients with progressive relapsing (PR) multiple sclerosis (MS) may accrue disability by incomplete recovery from acute exacerbations and by ongoing deterioration. In primary progressive (PP) MS, disability accumulates solely by continuous decline. Because it is the least common form of MS, there is scant information regarding the clinical characteristics of PRMS, but relapses are reportedly uncommon. The purpose of this study is to describe the clinical features of a cohort of patients with PRMS. Methods: A retrospective chart review of 16 patients diagnosed with PRMS at two academic MS centres over a four-year period. Results: Nine men and seven women had PRMS. The mean age at onset was 35.19/11.2 years. The most common presenting symptom was a progressive myelopathy. The mean disease duration was 10.19/8.5 years and the average time to first exacerbation was 4.19/3.7 years. Patients had an average of 2.89/2.3 relapses with an annualized relapse rate of 0.69/0.8. Time to Expanded Disability Status Scale (EDSS) 6.0 was strongly associated with time to first exacerbation. Although there was no correlation between the number of relapses and time to EDSS 6.0, there was a modest inverse relation between time to EDSS 6.0 and annualized relapse rate. Conclusions: Relapses in PRMS may occur more often than previously described and disability may accumulate more rapidly in PRMS than in PPMS. We suggest differentiating between these two forms of MS.
Lublin FD , Reingold SC.Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis . Neurology1996; 46: 907-911 .
2.
Andersson PB , Waubant E , Gee L , Goodkin DE.Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability . Arch Neurol1999; 56: 1138-1142 .
3.
Kremenchutzky M , Cottrell D , Rice G , Hader W , Baskerville J , Koopman Wet al.The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation . Brain1999; 122: 1941-1950 .
4.
Oshinsky RJ , Elfont RM , Lublin FD.Incidence and clinical characteristics of the progressive-relapsing form of MS . Neurology1998; 50: A209-A209 .
5.
Jacobs LD , Wende KE , Brownscheidle CM , Apatoff B , Coyle PK , Goodman Aet al.A profile of multiple sclerosis: the New York State Multiple Sclerosis Consortium . Mult Scler1999; 5: 369-376 .
6.
Confavreux C , Vukusic S , Moreau T , Adeleine P.Relapses and progression of disability in multiple sclerosis . N Engl J Med2000; 343: 1430-1438 .
7.
Bashir K , Whitaker JN.Clinical and laboratory features of primary progressive and secondary progressive MS . Neurology1999; 53: 765-771 .
8.
Confavreux C , Aimard G , Devic M.Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients . Brain1980; 103: 281-300 .
9.
Cottrell DA , Kremenchutzky M , Rice GP , Koopman WJ , Hader W , Baskerville Jet al.The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis . Brain1999; 122: 625-639 .
10.
McDonnell GV , Hawkins SA.Clinical study of primary progressive multiple sclerosis in Northern Ireland, UK . J Neurol Neurosurg Psychiatry1998; 64: 451-454 .
11.
Noseworthy JH , Lucchinetti C , Rodriguez M , Weinshenker BG.Multiple sclerosis . N Engl J Med2000; 343: 938-952 .
12.
Thompson AJ , Polman CH , Miller DH , McDonald WI , Brochet B , Filippi Met al.Primary progressive multiple sclerosis . Brain1997; 120: 1085-1096 .
13.
Weinshenker BG.Progressive forms of MS: classification streamlined or consensus overturned?Lancet2000; 355: 162-163 .
14.
Kurtzke JF.Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) . Neurology1983; 33: 1444-1452 .
15.
Weinshenker BG , Bass B , Rice GP , Noseworthy J , Carriere W , Baskerville Jet al.The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability . Brain1989; 112: 133-146 .
16.
Randomised double-blind placebo-controlled study of inter-feron beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group . Lancet1998; 352: 1498-1504 .
17.
Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS . Lancet1998; 352: 1491-1497 .
18.
Hartung HP , Gonsette R , Konig N , Kwiecinski H , Guseo A , Morrissey SPet al.Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial . Lancet2002; 360: 2018-2025 .
19.
Jacobs LD , Cookfair DL , Rudick RA , Herndon RM , Richert JR , Salazar AMet al.Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) . Ann Neurol1996; 39: 285-294 .
20.
Johnson KP , Brooks BR , Cohen JA , Ford CC , Goldstein J , Lisak RPet al.Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group . Neurology1995; 45: 1268-1276 .
21.
Lublin FD , Baier M , Cutter G.Effect of relapses on development of residual deficit in multiple sclerosis . Neurology2003; 61: 1528-1532 .
22.
Fischer JS , Rudick RA , Cutter GR , Reingold SC.The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force . Mult Scler1999; 5: 244-250 .
